.After elevating $170 million back in February, metabolic disease-focused BioAge Labs has filed to debut on the general public market.The Eli Lilly-partnered biotech wish to specify on the Nasdaq under the symbol “BIOA,” depending on to files filed with the Stocks as well as Exchange Commission. The firm has actually not publicly discussed an anticipated financial volume for the offering.The clinical-stage firm promotes lead applicant azelaprag, an orally provided tiny particle slated to enter into stage 2 testing in combo with semaglutide– offered by Novo Nordisk under brand name Wegovy for weight-loss– in the very first one-half of following year. Semaglutide is actually also offered as Ozempic and also Rybelsus through Novo for diabetes.
Apelin receptor agonist azelaprag is developed to integrate well with GLP-1 drugs, enhancing weight loss while preserving muscle mass. The investigational medicine was located to be well-tolerated one of 265 individuals throughout 8 stage 1 tests, depending on to BioAge.Recently, BioAge got the support of Lilly to manage a test incorporating azelaprag along with the Significant Pharma’s GLP-1/ GIP receptor agonist tirzepatide, which is actually industried for diabetes as Mounjaro as well as Zepbound for fat burning. The companions are currently conducting a phase 2 test of azelaprag as well as tirzepatide, along with topline end results anticipated in the third one-fourth of 2025.The biotech is also preparing a the hormone insulin level of sensitivity proof-of-concept test evaluating azelaprag as a monotherapy in the first half of following year to support possible indication expansion.
Additionally, the firm plans to inquire the FDA for consent in the second fifty percent of 2025 to release human testing for an NLRP3 prevention targeting metabolic health conditions and neuroinflammation.BioAge’s anticipated move to everyone market follows a slight uptick in considered biotech IPOs coming from Bicara Therapeutics and Zenas Biopharma. Zooming out, the current IPO garden is actually a “combined image,” with top quality companies still debuting on everyone markets, just in minimized amounts, according to PitchBook.